NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Aug 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
3/8 — Basic
Priority Review
TRENTAL (pentoxifylline) by Bausch Health is clinical pharmacology mode of action: pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. First approved in 1984.
Drug data last refreshed 23m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRENTAL (pentoxifylline) is an oral small-molecule xanthine derivative approved in 1984 for chronic peripheral arterial disease. It improves blood flow and tissue oxygenation by decreasing blood viscosity and enhancing erythrocyte flexibility. The drug modifies leukocyte properties and increases microcirculatory perfusion in patients with intermittent claudication and related ischemic conditions.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30); expect reduced marketing investment and team downsizing as generic alternatives gain market share.
Mechanism of Action
CLINICAL PHARMACOLOGY Mode of Action: Pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. In patients with chronic peripheral arterial disease, this increases blood flow to the affected microcirculation and enhances tissue oxygenation. The precise…
Worked on TRENTAL at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.